CU23804B7 - Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicas - Google Patents
Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicasInfo
- Publication number
- CU23804B7 CU23804B7 CU20090117A CU20090117A CU23804B7 CU 23804 B7 CU23804 B7 CU 23804B7 CU 20090117 A CU20090117 A CU 20090117A CU 20090117 A CU20090117 A CU 20090117A CU 23804 B7 CU23804 B7 CU 23804B7
- Authority
- CU
- Cuba
- Prior art keywords
- treatment
- glutamatergical
- benzotriazinone
- composite
- replaced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención se refiere a la prevención y tratamiento de insuficiencia cerebral, incluyendo incremento del funcionamiento de receptores en la sinapsis en las redes cerebrales responsables de comportamientos de orden superior. Estas redes cerebrales están implicadas en las capacidades cognitivas relacionadas con la alteración de la memoria, tal como se observa en una variedad de demencias y en desequilibrios de la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Parkinson, esquizofrenia y trastornos afectivos. En un aspecto particular, la presente invención se refiere a un compuesto útil para el tratamiento de dichas condiciones y a métodos para utilizar este compuesto para dicho tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87850307P | 2007-01-03 | 2007-01-03 | |
| US92143307P | 2007-04-02 | 2007-04-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20090117A7 CU20090117A7 (es) | 2011-10-05 |
| CU23804B7 true CU23804B7 (es) | 2012-03-15 |
Family
ID=39608956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20090117A CU23804B7 (es) | 2007-01-03 | 2009-07-03 | Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicas |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8173644B2 (es) |
| EP (1) | EP2144506B1 (es) |
| JP (1) | JP5139446B2 (es) |
| CN (1) | CN101616592B (es) |
| AP (1) | AP2502A (es) |
| AR (1) | AR064740A1 (es) |
| AT (1) | ATE527269T1 (es) |
| AU (1) | AU2007342365B2 (es) |
| BR (1) | BRPI0720749A2 (es) |
| CA (1) | CA2674460C (es) |
| CR (1) | CR10906A (es) |
| CU (1) | CU23804B7 (es) |
| CY (1) | CY1112493T1 (es) |
| DK (1) | DK2144506T3 (es) |
| EA (1) | EA017437B1 (es) |
| EC (1) | ECSP099499A (es) |
| ES (1) | ES2374995T3 (es) |
| GE (1) | GEP20125438B (es) |
| GT (1) | GT200900189A (es) |
| HK (1) | HK1140105A1 (es) |
| HN (1) | HN2009001268A (es) |
| HR (1) | HRP20110970T1 (es) |
| IL (1) | IL199651A (es) |
| MA (1) | MA31160B1 (es) |
| ME (1) | ME00819B (es) |
| MX (1) | MX2009007242A (es) |
| MY (1) | MY154877A (es) |
| NI (1) | NI200900131A (es) |
| NZ (1) | NZ578293A (es) |
| PL (1) | PL2144506T3 (es) |
| PT (1) | PT2144506E (es) |
| RS (1) | RS52108B (es) |
| SG (1) | SG163545A1 (es) |
| SI (1) | SI2144506T1 (es) |
| SV (1) | SV2009003322A (es) |
| TN (1) | TN2009000277A1 (es) |
| WO (1) | WO2008085506A1 (es) |
| ZA (1) | ZA200904826B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010514837A (ja) * | 2007-01-03 | 2010-05-06 | コーテックス ファーマシューティカルズ， インコーポレイテッド | グルタミン酸作動性シナプス反応を強化するための３−置換−［１，２，３］ベンゾトリアジノン化合物 |
| AU2008254960B2 (en) | 2007-05-17 | 2014-11-27 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
| US8119632B2 (en) | 2007-08-10 | 2012-02-21 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
| ES2560095T3 (es) | 2007-08-10 | 2016-02-17 | Cortex Pharmaceuticals, Inc. | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas |
| US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| EP2784065B1 (en) | 2011-11-22 | 2016-10-05 | Beijing Medisan Technology Co. Ltd. | Glycine reuptake inhibitor and use thereof |
| FR3019464B1 (fr) | 2014-04-07 | 2016-05-06 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| FR3034019B1 (fr) * | 2015-03-26 | 2017-03-17 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent |
| PE20180500A1 (es) | 2015-06-26 | 2018-03-09 | Takeda Pharmaceuticals Co | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 |
| CN106226509B (zh) * | 2016-08-12 | 2019-09-06 | 中国人民解放军第四军医大学 | 一种在小鼠前扣带回皮层诱发dse现象的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| FR2597103B1 (fr) | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| DK1156043T3 (da) | 1992-07-24 | 2004-03-01 | Univ California | Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| ATE174915T1 (de) * | 1994-10-31 | 1999-01-15 | Merck Patent Gmbh | Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| WO1998011892A1 (en) | 1996-09-17 | 1998-03-26 | The Regents Of The University Of California | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| AU751384B2 (en) | 1998-02-18 | 2002-08-15 | Neurosearch A/S | Novel compounds and their use as positive AMPA receptor modulators |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| CA2463592A1 (en) * | 2001-11-26 | 2003-06-05 | Cortex Pharmaceuticals, Inc. | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| JP2003238555A (ja) * | 2002-02-20 | 2003-08-27 | Sumitomo Pharmaceut Co Ltd | 細胞死抑制剤 |
| AUPS255202A0 (en) | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| AU2004204814B2 (en) * | 2003-01-13 | 2009-10-08 | Cortex Pharmaceuticals, Inc. | Method of treating cognitive decline due to sleep deprivation and stress |
| GB0317482D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| JP2010514837A (ja) | 2007-01-03 | 2010-05-06 | コーテックス ファーマシューティカルズ， インコーポレイテッド | グルタミン酸作動性シナプス反応を強化するための３−置換−［１，２，３］ベンゾトリアジノン化合物 |
| AU2008254960B2 (en) | 2007-05-17 | 2014-11-27 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
| ES2560095T3 (es) | 2007-08-10 | 2016-02-17 | Cortex Pharmaceuticals, Inc. | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas |
| CN101801939A (zh) | 2007-09-20 | 2010-08-11 | 科泰克斯药品公司 | 用于增强谷氨酸能突触反应的3-取代1,2,3-三嗪-4-酮类和3-取代1,3-嘧啶酮类 |
-
2007
- 2007-12-28 BR BRPI0720749-2A patent/BRPI0720749A2/pt not_active Application Discontinuation
- 2007-12-28 EP EP07868093A patent/EP2144506B1/en active Active
- 2007-12-28 NZ NZ578293A patent/NZ578293A/en not_active IP Right Cessation
- 2007-12-28 US US12/448,784 patent/US8173644B2/en not_active Expired - Fee Related
- 2007-12-28 SG SG201004695-1A patent/SG163545A1/en unknown
- 2007-12-28 DK DK07868093.1T patent/DK2144506T3/da active
- 2007-12-28 ES ES07868093T patent/ES2374995T3/es active Active
- 2007-12-28 ME MEP-2009-238A patent/ME00819B/me unknown
- 2007-12-28 AP AP2009004931A patent/AP2502A/xx active
- 2007-12-28 PL PL07868093T patent/PL2144506T3/pl unknown
- 2007-12-28 JP JP2009544857A patent/JP5139446B2/ja not_active Expired - Fee Related
- 2007-12-28 MY MYPI20092796A patent/MY154877A/en unknown
- 2007-12-28 RS RS20110587A patent/RS52108B/en unknown
- 2007-12-28 AU AU2007342365A patent/AU2007342365B2/en not_active Ceased
- 2007-12-28 PT PT07868093T patent/PT2144506E/pt unknown
- 2007-12-28 GE GEAP200711384A patent/GEP20125438B/en unknown
- 2007-12-28 MX MX2009007242A patent/MX2009007242A/es active IP Right Grant
- 2007-12-28 CA CA2674460A patent/CA2674460C/en not_active Expired - Fee Related
- 2007-12-28 WO PCT/US2007/026416 patent/WO2008085506A1/en active Application Filing
- 2007-12-28 ZA ZA200904826A patent/ZA200904826B/xx unknown
- 2007-12-28 EA EA200900925A patent/EA017437B1/ru not_active IP Right Cessation
- 2007-12-28 SI SI200730806T patent/SI2144506T1/sl unknown
- 2007-12-28 CN CN2007800508375A patent/CN101616592B/zh not_active Expired - Fee Related
- 2007-12-28 AT AT07868093T patent/ATE527269T1/de active
-
2008
- 2008-01-03 AR ARP080100022A patent/AR064740A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 TN TNP2009000277A patent/TN2009000277A1/fr unknown
- 2009-07-01 NI NI200900131A patent/NI200900131A/es unknown
- 2009-07-02 CR CR10906A patent/CR10906A/es not_active Application Discontinuation
- 2009-07-02 GT GT200900189A patent/GT200900189A/es unknown
- 2009-07-02 SV SV2009003322A patent/SV2009003322A/es unknown
- 2009-07-02 IL IL199651A patent/IL199651A/en active IP Right Grant
- 2009-07-03 HN HN2009001268A patent/HN2009001268A/es unknown
- 2009-07-03 CU CU20090117A patent/CU23804B7/es active IP Right Grant
- 2009-07-07 EC EC2009009499A patent/ECSP099499A/es unknown
- 2009-07-31 MA MA32135A patent/MA31160B1/fr unknown
-
2010
- 2010-06-29 HK HK10106349.3A patent/HK1140105A1/xx not_active IP Right Cessation
-
2011
- 2011-12-23 HR HR20110970T patent/HRP20110970T1/hr unknown
- 2011-12-28 CY CY20111101287T patent/CY1112493T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23804B7 (es) | Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicas | |
| TN2009000278A1 (en) | 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
| CR20130339A (es) | Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos | |
| ECSP12011908A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO | |
| ECSP12011692A (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| GT200900231A (es) | Moduladores 2-aminopirimidina del receptor de histamina h4 | |
| CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
| EA201491534A1 (ru) | Ингибиторы бета-секретазы | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| CL2012003212A1 (es) | Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson. | |
| ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
| WO2013029060A3 (en) | Compositions and methods for treating neurodegenerative disease | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| EP2750606A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS | |
| UY34991A (es) | Inhibidores de la beta-secretasa | |
| BR112013018296A2 (pt) | tratamento de disfunções cognitivas em esquizofrenia | |
| BR0214425A (pt) | Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas | |
| CL2012003437A1 (es) | Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda; composicion farmaceutica; y utilizacion para el tratamiento de trastornos cognitivos asociados al envejecimiento cerebral y a enfermedades neurodegenerativas tal como la enfermedad de alzheimer. | |
| CL2007003719A1 (es) | Compuestos derivados de espiro-piperidina, moduladores del receptor de vasopresina v1a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como dismenorrea, hipertension, ansiedad y trastornos depresivos. | |
| DE602008004563D1 (de) | Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung | |
| UA93306C2 (ru) | Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций | |
| CL2018001633A1 (es) | Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos | |
| GT200900150A (es) | Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |